United States - English - NLM (National Library of Medicine)

consilii llc - salicylic acid (unii: o414pz4lpz) (salicylic acid - unii:o414pz4lpz), matrine (unii: n390w430ac) (matrine - unii:n390w430ac) - corn and callus remover for the removal of corns and calluses relieves pain by removing corns and calluses discomfort persists

United States - English - NLM (National Library of Medicine)

golden life health products limited - nicotinamide ribotide (unii: 2kg6qx4w0v) (nicotinamide ribotide - unii:2kg6qx4w0v), resveratrol (unii: q369o8926l) (resveratrol - unii:q369o8926l), matrine (unii: n390w430ac) (matrine - unii:n390w430ac) - this product is not recommended for cancer patients,women, and people age below 18 years oldbased on scientific research. lf you have any questions,please consult doctors or professionals for more information. every capsule contains: 150mg nicotinamide mononucleotide for nad+ support. 200mg testosterone for male support

United States - English - NLM (National Library of Medicine)

xiamen chenhai biotechnology co.ltd - matrine 0.8%(m/m0) -

United States - English - NLM (National Library of Medicine)

anhui cao coral biology science and technology co., ltd - matrine 0.8%(m/m0) -

United States - English - NLM (National Library of Medicine)

shantou youjia e-commerce co.,ltd. - matrine (unii: n390w430ac) (matrine - unii:n390w430ac), bassia scoparia fruit (unii: 04w97z676y) (bassia scoparia fruit - unii:04w97z676y), gentiana lutea root (unii: s72o3284ms) (gentiana lutea root - unii:s72o3284ms), zanthoxylum bungeanum fruit (unii: 3cip16a418) (zanthoxylum bungeanum fruit - unii:3cip16a418), glycerin (unii: pdc6a3c0ox) (glycerin - unii:pdc6a3c0ox) -

India - English - Central Drugs Standard Control Organization

novartis - ferrous succ.,succinic acid,folic acid,vit.b12 - cap - 100mg,110mg,0.5mg,5mcg - 30

United States - English - NLM (National Library of Medicine)

weifang hongyang pharmacy co., ltd. - chlorhexidine acetate (unii: 5908zuf22y) (chlorhexidine - unii:r4ko0dy52l) - clean and care the skin and mucosa of adults. do not use when wound or skin infection. it should be cautiously used if you are kind of allergic constitution or you have inflammation. if irritation or discomfort occurs, discontinue the use and consult a physician. this product can inhibit staphylococcus aureus, colibacillus and candida albicans. used to clean and care the skin and mucosa of adults. spray on the area of skin or mucosa evenly, do not need clean.

New Zealand - English - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - itraconazole 100mg;   - capsule - 100 mg - active: itraconazole 100mg   excipient: erythrosine gelatin   hypromellose indigo carmine macrogol 20000 sugar spheres titanium dioxide - sporanox capsules are indicated for the following conditions: - treatment of vulvovaginal candidiasis. - treatment of pityriasis versicolor. - treatment of dermatomycosis – including highly keratinised regions as in plantar tinea pedis and palmer tinea manus. - treatment of fungal keratitis. - treatment of oral candidiasis. - treatment of onychomycosis caused by dermatophytes and/or yeasts. - systemic mycoses, only in the following fungal infections: o treatment of systemic aspergillosis and candidiasis, o treatment of histoplasmosis, o histoplasmosis, maintenance therapy only in aids patients. o treatment of sporotrichosis (including lymphocutaneous/cutaneous and extracutaneous), o treatment of paracoccidioidomycosis, o treatment of chromomycosis, o treatment of blastomycosis.

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - itraconazole, quantity: 10 mg/ml - oral liquid, solution - excipient ingredients: propylene glycol; hydroxypropylbetadex; saccharin sodium; purified water; caramel; sorbitol solution (70 per cent) (non-crystallising); sodium hydroxide; hydrochloric acid; flavour - sporanox oral solution is indicated for: * the treatment of oral and/or oesophageal candidiasis in hiv-positive or other immunocompromised patients. * prophylaxis of fungal infections in neutropenic patients.

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - itraconazole, quantity: 100 mg - capsule, hard - excipient ingredients: macrogol 20000; titanium dioxide; gelatin; hypromellose; indigo carmine; erythrosine; maize starch; sucrose - sporanox is indicated for use in adults for the treatment of: superficial dermatomycoses not responding to topical treatment. fungal keratitis which has failed to respond to topical treatment or where the disease is either progressing rapidly or is immediately sight threatening. pityriasis versicolor not responding to any other treatment. vulvovaginal candidiasis not responding to topical treatment. oral candidiasis in immunocompromised patients. onychomycosis caused by dermatophytes. systemic mycoses: -systemic aspergillosis, histoplasmosis, sporotrichosis. -treatment and maintenance therapy in aids patients with disseminated or chronic pulmonary histoplasmosis infection. -treatment of oropharyngeal and/or oesophageal candidiasis when fist line systemic antifungal therapy is inappropriate or has proven ineffective. -treatment of non-invasive candidiasis in non-neutropenic patients when first-line systemic antifungal therapy is inappropriate or has proven ineffective. this may be due to underlying pathology,